AAPL342.46-1.01 (-0.29%) ▼|ABBV283.23-2.19 (-0.77%) ▼|ABT103.77-1.12 (-1.07%) ▼|ACN231.93+2.25 (+0.98%) ▲|ADBE244.88-0.33 (-0.13%) ▼|AMAT423.98+14.69 (+3.59%) ▲|AMD548.48+19.73 (+3.73%) ▲|AMGN427.01-5.49 (-1.27%) ▼|AMT182.77-2.50 (-1.35%) ▼|AMZN262.97+12.97 (+5.19%) ▲|AVGO339.14+10.39 (+3.16%) ▲|AXP313.39-0.21 (-0.07%) ▼|BA191.44+1.23 (+0.64%) ▲|BAC50.53-0.71 (-1.38%) ▼|BKNG161.04-2.41 (-1.47%) ▼|BLK1,128.55-5.83 (-0.51%) ▼|BMY58.66-1.10 (-1.83%) ▼|BNY143.11-0.20 (-0.14%) ▼|BRK-B530.62-1.41 (-0.26%) ▼|C122.91-1.35 (-1.09%) ▼|CAT730.66-0.10 (-0.01%) ▼|CL93.04-1.07 (-1.14%) ▼|CMCSA21.72-0.19 (-0.84%) ▼|COF199.66-2.08 (-1.03%) ▼|COP144.69-1.82 (-1.24%) ▼|COST990.00+0.89 (+0.09%) ▲|CRM239.54-1.16 (-0.48%) ▼|CSCO107.35-0.04 (-0.04%) ▼|CVS91.22-1.14 (-1.23%) ▼|CVX223.64-1.35 (-0.60%) ▼|DE629.94-11.92 (-1.86%) ▼|DHR225.22-3.82 (-1.67%) ▼|DIS109.71-0.89 (-0.80%) ▼|DUK119.56-1.92 (-1.58%) ▼|EMR161.73+0.26 (+0.16%) ▲|FDX292.88-0.67 (-0.23%) ▼|GD341.62-2.61 (-0.76%) ▼|GE312.35-1.48 (-0.47%) ▼|GEV921.84+0.64 (+0.07%) ▲|GILD154.68-1.51 (-0.97%) ▼|GM82.42-1.54 (-1.83%) ▼|GOOG341.25+4.34 (+1.29%) ▲|GOOGL345.42+4.83 (+1.42%) ▲|GS881.36+0.10 (+0.01%) ▲|HD309.40-0.23 (-0.07%) ▼|HON211.09-0.33 (-0.15%) ▼|IBM236.12+3.98 (+1.71%) ▲|INTC94.58+4.73 (+5.26%) ▲|INTU321.82-3.33 (-1.02%) ▼|ISRG432.22+5.52 (+1.29%) ▲|JNJ252.70-2.86 (-1.12%) ▼|JPM335.60-4.12 (-1.21%) ▼|KO93.60-0.30 (-0.32%) ▼|LIN501.56+3.13 (+0.63%) ▲|LLY1,248.36-8.67 (-0.69%) ▼|LMT549.50-2.59 (-0.47%) ▼|LOW195.48-1.91 (-0.97%) ▼|LRCX278.52+14.58 (+5.52%) ▲|MA613.06-4.36 (-0.71%) ▼|MCD242.34-0.64 (-0.26%) ▼|MDLZ63.57-0.34 (-0.53%) ▼|MDT92.88-1.88 (-1.98%) ▼|META703.34-5.99 (-0.84%) ▼|MMM163.79-0.96 (-0.58%) ▼|MO74.23-0.88 (-1.17%) ▼|MRK144.60-1.35 (-0.93%) ▼|MS179.96-0.61 (-0.34%) ▼|MSFT534.15+5.10 (+0.96%) ▲|MU919.77+40.93 (+4.66%) ▲|NEE78.56-1.24 (-1.55%) ▼|NFLX69.68-0.86 (-1.21%) ▼|NKE36.84-0.30 (-0.79%) ▼|NOW143.89+1.92 (+1.35%) ▲|NVDA219.54+5.41 (+2.53%) ▲|ORCL130.69+2.46 (+1.91%) ▲|PEP132.38+0.89 (+0.68%) ▲|PFE29.30-0.29 (-0.96%) ▼|PG157.22-2.13 (-1.34%) ▼|PLTR196.03+10.00 (+5.38%) ▲|PM201.78-3.42 (-1.67%) ▼|QCOM173.83+1.72 (+1.00%) ▲|RTX191.84-2.09 (-1.08%) ▼|SBUX97.95+0.43 (+0.44%) ▲|SCHW90.19-1.77 (-1.92%) ▼|SO89.67-1.52 (-1.66%) ▼|SPG203.50-1.94 (-0.94%) ▼|T23.11-0.34 (-1.43%) ▼|TMO677.03-12.97 (-1.88%) ▼|TMUS157.62-1.48 (-0.93%) ▼|TSLA367.63+12.91 (+3.64%) ▲|TXN274.55-1.93 (-0.70%) ▼|UBER70.39+0.04 (+0.05%) ▲|UNH401.77+0.34 (+0.08%) ▲|UNP286.76-2.28 (-0.79%) ▼|UPS97.32-0.17 (-0.17%) ▼|USB58.21-0.53 (-0.89%) ▼|V401.95-0.67 (-0.17%) ▼|VZ44.11-0.68 (-1.52%) ▼|WFC82.17-1.71 (-2.03%) ▼|WMT118.35-0.47 (-0.39%) ▼|XOM177.58-1.40 (-0.78%) ▼|AAPL342.46-1.01 (-0.29%) ▼|ABBV283.23-2.19 (-0.77%) ▼|ABT103.77-1.12 (-1.07%) ▼|ACN231.93+2.25 (+0.98%) ▲|ADBE244.88-0.33 (-0.13%) ▼|AMAT423.98+14.69 (+3.59%) ▲|AMD548.48+19.73 (+3.73%) ▲|AMGN427.01-5.49 (-1.27%) ▼|AMT182.77-2.50 (-1.35%) ▼|AMZN262.97+12.97 (+5.19%) ▲|AVGO339.14+10.39 (+3.16%) ▲|AXP313.39-0.21 (-0.07%) ▼|BA191.44+1.23 (+0.64%) ▲|BAC50.53-0.71 (-1.38%) ▼|BKNG161.04-2.41 (-1.47%) ▼|BLK1,128.55-5.83 (-0.51%) ▼|BMY58.66-1.10 (-1.83%) ▼|BNY143.11-0.20 (-0.14%) ▼|BRK-B530.62-1.41 (-0.26%) ▼|C122.91-1.35 (-1.09%) ▼|CAT730.66-0.10 (-0.01%) ▼|CL93.04-1.07 (-1.14%) ▼|CMCSA21.72-0.19 (-0.84%) ▼|COF199.66-2.08 (-1.03%) ▼|COP144.69-1.82 (-1.24%) ▼|COST990.00+0.89 (+0.09%) ▲|CRM239.54-1.16 (-0.48%) ▼|CSCO107.35-0.04 (-0.04%) ▼|CVS91.22-1.14 (-1.23%) ▼|CVX223.64-1.35 (-0.60%) ▼|DE629.94-11.92 (-1.86%) ▼|DHR225.22-3.82 (-1.67%) ▼|DIS109.71-0.89 (-0.80%) ▼|DUK119.56-1.92 (-1.58%) ▼|EMR161.73+0.26 (+0.16%) ▲|FDX292.88-0.67 (-0.23%) ▼|GD341.62-2.61 (-0.76%) ▼|GE312.35-1.48 (-0.47%) ▼|GEV921.84+0.64 (+0.07%) ▲|GILD154.68-1.51 (-0.97%) ▼|GM82.42-1.54 (-1.83%) ▼|GOOG341.25+4.34 (+1.29%) ▲|GOOGL345.42+4.83 (+1.42%) ▲|GS881.36+0.10 (+0.01%) ▲|HD309.40-0.23 (-0.07%) ▼|HON211.09-0.33 (-0.15%) ▼|IBM236.12+3.98 (+1.71%) ▲|INTC94.58+4.73 (+5.26%) ▲|INTU321.82-3.33 (-1.02%) ▼|ISRG432.22+5.52 (+1.29%) ▲|JNJ252.70-2.86 (-1.12%) ▼|JPM335.60-4.12 (-1.21%) ▼|KO93.60-0.30 (-0.32%) ▼|LIN501.56+3.13 (+0.63%) ▲|LLY1,248.36-8.67 (-0.69%) ▼|LMT549.50-2.59 (-0.47%) ▼|LOW195.48-1.91 (-0.97%) ▼|LRCX278.52+14.58 (+5.52%) ▲|MA613.06-4.36 (-0.71%) ▼|MCD242.34-0.64 (-0.26%) ▼|MDLZ63.57-0.34 (-0.53%) ▼|MDT92.88-1.88 (-1.98%) ▼|META703.34-5.99 (-0.84%) ▼|MMM163.79-0.96 (-0.58%) ▼|MO74.23-0.88 (-1.17%) ▼|MRK144.60-1.35 (-0.93%) ▼|MS179.96-0.61 (-0.34%) ▼|MSFT534.15+5.10 (+0.96%) ▲|MU919.77+40.93 (+4.66%) ▲|NEE78.56-1.24 (-1.55%) ▼|NFLX69.68-0.86 (-1.21%) ▼|NKE36.84-0.30 (-0.79%) ▼|NOW143.89+1.92 (+1.35%) ▲|NVDA219.54+5.41 (+2.53%) ▲|ORCL130.69+2.46 (+1.91%) ▲|PEP132.38+0.89 (+0.68%) ▲|PFE29.30-0.29 (-0.96%) ▼|PG157.22-2.13 (-1.34%) ▼|PLTR196.03+10.00 (+5.38%) ▲|PM201.78-3.42 (-1.67%) ▼|QCOM173.83+1.72 (+1.00%) ▲|RTX191.84-2.09 (-1.08%) ▼|SBUX97.95+0.43 (+0.44%) ▲|SCHW90.19-1.77 (-1.92%) ▼|SO89.67-1.52 (-1.66%) ▼|SPG203.50-1.94 (-0.94%) ▼|T23.11-0.34 (-1.43%) ▼|TMO677.03-12.97 (-1.88%) ▼|TMUS157.62-1.48 (-0.93%) ▼|TSLA367.63+12.91 (+3.64%) ▲|TXN274.55-1.93 (-0.70%) ▼|UBER70.39+0.04 (+0.05%) ▲|UNH401.77+0.34 (+0.08%) ▲|UNP286.76-2.28 (-0.79%) ▼|UPS97.32-0.17 (-0.17%) ▼|USB58.21-0.53 (-0.89%) ▼|V401.95-0.67 (-0.17%) ▼|VZ44.11-0.68 (-1.52%) ▼|WFC82.17-1.71 (-2.03%) ▼|WMT118.35-0.47 (-0.39%) ▼|XOM177.58-1.40 (-0.78%) ▼|
15.1 C
New York
Monday, October 19, 2026

Tag: Amgen

newssourceFORcompanycontentinformation1releasesmarket

Neuroendocrine Prostate Cancer Market to Witness Growth at a 25% CAGR by 2036 Due to the Emergence of Emerging agents, including DLL3-targeted Therapies, ADCs,...

The neuroendocrine prostate cancer market is expected to grow steadily, driven by the rising recognition of NEPC as an aggressive and treatment-resistant form of...

Neuroendocrine Prostate Cancer Market to Witness Growth at a 25% CAGR by 2036 Due to the Emergence of Emerging agents, including DLL3-targeted Therapies, ADCs,...

The neuroendocrine prostate cancer market is expected to grow steadily, driven by the rising recognition of NEPC as an aggressive and treatment-resistant form of...

Prifemilast Demonstrates Superior Efficacy vs. Apremilast in Newsoara’s Head-to-Head Phase 3 Psoriasis Trial; cAMPfield Advancing the Potential Best-in-Class Oral PDE4 Inhibitor in IBD

In a head-to-head Phase 3 trial, prifemilast nearly doubled the rate of PASI 75 response compared with apremilast and achieved superiority on both co-primary...

All 365 SPJIMR PGDM Class of 2028 participants placed; median stipend up 17% to ₹2 lakhs a month

91 companies take part, including 37 first-time recruitersKey pointers:365 participants placed, representing 100% of the Class of 2028₹2 lakhs per month median stipend, up...

Questex’s DPHARM Announces Senior Leadership and Keynotes for the 16th Annual Conference

BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- DPHARM, the leading innovation event for clinical trial operation executives, announces the 16th annual conference agenda including its senior leadership and keynotes. DPHARM which is now part of Questex’s Fierce Life Sciences, takes place September 15-16, 2026, at the Sheraton Boston Hotel.

New 5W AI Visibility Index: Pharma Spends Billions on DTC Ads. The AI Engines Talk About Eli Lilly and Novo Nordisk Anyway

Drugmakers run the largest direct-to-consumer advertising category in the United States. New 5W research finds AI citation share does not follow the ad budget...

Harbour BioMed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape

The case, originally filed in 2021 by Harbour Antibodies, asserted that Amgen and Teneobio (an Amgen subsidiary) infringed patents protecting Harbour's groundbreaking antibody discovery...

GlycoNex Announces Positive Topline Results for Phase III Clinical Trial of Denosumab Biosimilar SPD8

NEW TAIPEI CITY, June 10, 2026 /PRNewswire/ -- GlycoNex, Inc. (4168, hereinafter referred to as GNX), today announced that the Phase III clinical trial...

AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS

VESALIUS-CV Subgroup Results Show Repatha® Reduces Risk of First Major Cardiovascular Events by 29% in People Living with High-Risk DiabetesNew Real-World Data Highlight Treatment...

Pediatric Relapsed/Refractory Neuroblastoma Market is on an Upward Trend, Driven by Innovation and Unmet Need | DelveInsight

The outlook for the neuroblastoma treatment market is optimistic, fueled by progress in targeted therapies and immunotherapies. GD2-targeted immunotherapy is increasingly being incorporated into...

Pediatric Relapsed/Refractory Neuroblastoma Market is on an Upward Trend, Driven by Innovation and Unmet Need | DelveInsight

The outlook for the neuroblastoma treatment market is optimistic, fueled by progress in targeted therapies and immunotherapies. GD2-targeted immunotherapy is increasingly being incorporated into...

Tumor-Infiltrating Lymphocyte Therapy Market Gains Momentum with Expanding Oncology Applications | DelveInsight

Over the last ten years, cell-based immunotherapy has emerged as a promising approach for treating solid tumors. Several companies, including Iovance Biotherapeutics, Obsidian Therapeutics,...

Tumor-Infiltrating Lymphocyte Therapy Market Gains Momentum with Expanding Oncology Applications | DelveInsight

Over the last ten years, cell-based immunotherapy has emerged as a promising approach for treating solid tumors. Several companies, including Iovance Biotherapeutics, Obsidian Therapeutics,...

The Galien Foundation Announces 2025 Prix Galien USA Nominees for “Best Biotechnology Product,” “Best Pharmaceutical Product” and “Best Product for Rare/Orphan Diseases”

NEW YORK, Aug. 11, 2025 /PRNewswire/ -- The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, today announced the...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsAmgen

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers